India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease

India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease
India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease

  • Seeks patent on new therapy for drug that employs concentrations of THC
  • Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss
  • IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product


India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://cnw.fm/UhYF1). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron damage.

This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.

Read the full article

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer